Stenzl, A., Witfies, J.A., Cowan, N.C., De Santis, M., Lebret, T., Merseburger, A.S., et al. (2011) Guidelines on Bladder Cancer Muscle Invasive and Metastatic. European Urology, 59, 1009-1018.
https://doi.org/10.1016/j.eururo.2011.03.023

has been cited by the following article:

• TITLE: Therapeutic Specificities and Prognosis of Advanced Stage and Metastatic Bladder Cancers in a Tunisian University Hospital

  AUTHORS: Zaied Sonia, Khechine Wiem, Bourigua Rim, Abbess Ibtissem, Ktari Kamel, Ben Ali Yosri, Daldoul Amira

  KEYWORDS: Bladder Neoplasms, Epidemiology, Treatment, Prognosis

  JOURNAL NAME: Open Access Library Journal, Vol.4 No.10, October 18, 2017

  ABSTRACT: In Tunisia, bladder cancer represents the first urological cancer before even prostate cancer. However, its diagnosis is often delayed to the stage of invasive tumor. Systemic chemotherapy represents an option for inoperable and/or metastatic forms. Our study’s aims were to report our center’s therapeutic results for locally advanced and metastatic forms of bladder cancer and to analyze its prognosis factors. In our 40 patients with bladder cancer advanced stages (locally advanced and metastatic), transitional cell carcinoma was the most common histological type (82.5%); mean age at diagnosis was 63.3 ± 10.5 years with a sex ratio equal to 12.3; radical cystectomy and radiation therapy were performed separately both in 35% of cases and chemotherapy in 60%; cisplatin associated with gemcitabine was the most used regimen and navelbine monotherapy was used as second-line chemotherapy; median overall survival was 14.4 months, and its influencing factors according to our results were: ECOG score, T and M tumor stages, primary tumor surgery and adjuvant chemotherapy.